SEC Form 4 · accession 0000899243-17-008973
AVEO PHARMACEUTICALS INC · AVEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony B Evnin
Director
Period of report
Mar 28, 2017
Accepted (ET)
Mar 30, 2017 · 9:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001325879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 28, 2017 | J | 250,000 | $0.50 | A | 418,414 | D | |
| Common StockF2 | holding | — | — | — | 1,147,068 | I | By Funds |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reports the purchase of shares in the underwritten public offering of common stock of AVEO Pharmaceuticals, Inc.
- F2Consists of (a) 206,452 shares of common stock held by Venrock Associates, or VA, (b) 917,569 shares of common stock held by Venrock Associates III, L.P., or VA III, (c) 22,938 shares of common stock held by Venrock Entrepreneurs Fund III, L.P., or VEF III, and (d) 109 shares of common stock held by VEF Management III, LLC, or VEFM III. Dr. Evnin is a General Partner of VA. Venrock Management III, LLC, or VM III, is the sole General Partner of VA III. VEFM III, is the sole General Partner of VEF III. Dr. Evnin is a Member of VM III and VEFM III. Dr. Evnin expressly disclaims beneficial ownership over all shares held by or on behalf of VA, VA III, VEF III, VM III, and VEFM III, except to the extent of his indirect pecuniary interest therein.